+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Global Anaplastic Lymphoma Kinase (ALK) Inhibitors Market 2021-2025

  • ID: 5117615
  • Report
  • April 2021
  • Region: Global
  • 120 Pages
  • TechNavio
1h Free Analyst Time
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

FEATURED COMPANIES

  • Bio-Techne Corp.
  • F. Hoffmann-La Roche Ltd.
  • Helsinn Healthcare SA
  • Merck KGaA
  • Novartis AG
  • Pfizer Inc.
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The publisher has been monitoring the anaplastic lymphoma kinase (ALK) inhibitors market and it is poised to grow by $ 3.43 billion during 2021-2025, progressing at a CAGR of almost 22% during the forecast period. The report on anaplastic lymphoma kinase (ALK) inhibitors market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current global market scenario, latest trends and drivers, and the overall market environment. The market is driven by the high target affinity and specificity of ALK inhibitors, high prevalence of lung cancer, and presence of patient assistance programs. In addition, the high target affinity and specificity of ALK inhibitors is anticipated to boost the growth of the market as well.

The anaplastic lymphoma kinase (ALK) inhibitors market analysis includes type segment and geographic landscape.

The anaplastic lymphoma kinase (ALK) inhibitors market is segmented as below:

By Type
  • Second-generation ALK inhibitors
  • First-generation ALK inhibitors
  • Third-generation ALK inhibitors

By Geographical Landscape
  • North America
  • Europe
  • Asia
  • ROW

This study identifies the expansion of research areas and combination therapies as one of the prime reasons driving the anaplastic lymphoma kinase (ALK) inhibitors market growth during the next few years. Also, strategic alliances and growing awareness about lung cancer will lead to sizable demand in the market.

The report on anaplastic lymphoma kinase (ALK) inhibitors market covers the following areas:
  • Anaplastic lymphoma kinase (ALK) inhibitors market sizing
  • Anaplastic lymphoma kinase (ALK) inhibitors market forecast
  • Anaplastic lymphoma kinase (ALK) inhibitors market industry analysis

The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading anaplastic lymphoma kinase (ALK) inhibitors market vendors that include Betta Pharmaceuticals Co. Ltd., Bio-Techne Corp., Chia Tai Tianqing Pharmaceutical Group Co. Ltd., F. Hoffmann-La Roche Ltd., Helsinn Healthcare SA, Merck KGaA, Novartis AG, Pfizer Inc., Takeda Pharmaceutical Co. Ltd., and Turning Point Therapeutics Inc. Also, the anaplastic lymphoma kinase (ALK) inhibitors market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.

The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast the accurate market growth.
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Bio-Techne Corp.
  • F. Hoffmann-La Roche Ltd.
  • Helsinn Healthcare SA
  • Merck KGaA
  • Novartis AG
  • Pfizer Inc.

Executive Summary
  • Market overview

Market Landscape
  • Market ecosystem
  • Value chain analysis

Market Sizing
  • Market definition
  • Market segment analysis
  • Market size 2020
  • Market outlook: Forecast for 2020 - 2025

Five Forces Analysis
  • Five forces summary
  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition

Market Segmentation by Type
  • Market segments
  • Comparison by Type
  • Second-generation ALK inhibitors - Market size and forecast 2020-2025
  • First-generation ALK inhibitors - Market size and forecast 2020-2025
  • Third-generation ALK inhibitors - Market size and forecast 2020-2025
  • Market opportunity by Type

Customer Landscape
Geographic Landscape
  • Geographic segmentation
  • Geographic comparison
  • North America - Market size and forecast 2020-2025
  • Europe - Market size and forecast 2020-2025
  • Asia - Market size and forecast 2020-2025
  • ROW - Market size and forecast 2020-2025
  • Key leading countries
  • Market opportunity by geography
  • Market drivers
  • Market challenges
  • Market trends

Vendor Landscape
  • Overview
  • Vendor landscape
  • Landscape disruption

Vendor Analysis
  • Vendors covered
  • Market positioning of vendors
  • Betta Pharmaceuticals Co. Ltd.
  • Bio-Techne Corp.
  • Chia Tai Tianqing Pharmaceutical Group Co. Ltd.
  • F. Hoffmann-La Roche Ltd.
  • Helsinn Healthcare SA
  • Merck KGaA
  • Novartis AG
  • Pfizer Inc.
  • Takeda Pharmaceutical Co. Ltd.
  • Turning Point Therapeutics Inc.

Appendix
  • Scope of the report
  • Currency conversion rates for US$
  • Research methodology
  • List of abbreviations

List of Exhibits
  • Key Finding 1
  • Key Finding 2
  • Key Finding 3
  • Key Finding 5
  • Key Finding 6
  • Key Finding 7
  • Key Finding 8
  • Parent market
  • Market characteristics
  • Offerings of vendors included in the market definition
  • Market segments
  • Global - Market size and forecast 2020 - 2025 ($ million)
  • Global market: Year-over-year growth 2020 - 2025 (%)
  • Five forces analysis 2020 & 2025
  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition - Five forces 2020
  • Type - Market share 2020-2025 (%)
  • Comparison by Type
  • Second-generation ALK inhibitors - Market size and forecast 2020-2025 ($ million)
  • Second-generation ALK inhibitors - Year-over-year growth 2020-2025 (%)
  • First-generation ALK inhibitors - Market size and forecast 2020-2025 ($ million)
  • First-generation ALK inhibitors - Year-over-year growth 2020-2025 (%)
  • Third-generation ALK inhibitors - Market size and forecast 2020-2025 ($ million)
  • Third-generation ALK inhibitors - Year-over-year growth 2020-2025 (%)
  • Market opportunity by Type
  • Customer landscape
  • Market share by geography 2020-2025 (%)
  • Geographic comparison
  • North America - Market size and forecast 2020-2025 ($ million)
  • North America - Year-over-year growth 2020-2025 (%)
  • Europe - Market size and forecast 2020-2025 ($ million)
  • Europe - Year-over-year growth 2020-2025 (%)
  • Asia - Market size and forecast 2020-2025 ($ million)
  • Asia - Year-over-year growth 2020-2025 (%)
  • ROW - Market size and forecast 2020-2025 ($ million)
  • ROW - Year-over-year growth 2020-2025 (%)
  • Key leading countries
  • Market opportunity by geography ($ million)
  • Impact of drivers and challenges
  • Vendor landscape
  • Landscape disruption
  • Industry risks
  • Vendors covered
  • Market positioning of vendors
  • Betta Pharmaceuticals Co. Ltd. - Overview
  • Betta Pharmaceuticals Co. Ltd. - Product and service
  • Betta Pharmaceuticals Co. Ltd. - Key offerings
  • Betta Pharmaceuticals Co. Ltd. - Key customers
  • Betta Pharmaceuticals Co. Ltd. - Segment focus
  • Bio-Techne Corp. - Overview
  • Bio-Techne Corp. - Business segments
  • Bio-Techne Corp. - Key offerings
  • Bio-Techne Corp. - Key customers
  • Bio-Techne Corp. - Segment focus
  • Chia Tai Tianqing Pharmaceutical Group Co. Ltd. - Overview
  • Chia Tai Tianqing Pharmaceutical Group Co. Ltd. - Product and service
  • Chia Tai Tianqing Pharmaceutical Group Co. Ltd. - Key offerings
  • Chia Tai Tianqing Pharmaceutical Group Co. Ltd. - Key customers
  • Chia Tai Tianqing Pharmaceutical Group Co. Ltd. - Segment focus
  • F. Hoffmann-La Roche Ltd. - Overview
  • F. Hoffmann-La Roche Ltd. - Business segments
  • F. Hoffmann-La Roche Ltd. - Key offerings
  • F. Hoffmann-La Roche Ltd. - Key customers
  • F. Hoffmann-La Roche Ltd. - Segment focus
  • Helsinn Healthcare SA - Overview
  • Helsinn Healthcare SA - Product and service
  • Helsinn Healthcare SA - Key offerings
  • Helsinn Healthcare SA - Key customers
  • Helsinn Healthcare SA - Segment focus
  • Merck KGaA - Overview
  • Merck KGaA - Business segments
  • Merck KGaA - Key offerings
  • Merck KGaA - Key customers
  • Merck KGaA - Segment focus
  • Novartis AG - Overview
  • Novartis AG - Business segments
  • Novartis AG - Key offerings
  • Novartis AG - Key customers
  • Novartis AG - Segment focus
  • Pfizer Inc. - Overview
  • Pfizer Inc. - Business segments
  • Pfizer Inc. - Key offerings
  • Pfizer Inc. - Key customers
  • Pfizer Inc. - Segment focus
  • Takeda Pharmaceutical Co. Ltd. - Overview
  • Takeda Pharmaceutical Co. Ltd. - Product and service
  • Takeda Pharmaceutical Co. Ltd. - Key offerings
  • Takeda Pharmaceutical Co. Ltd. - Key customers
  • Takeda Pharmaceutical Co. Ltd. - Segment focus
  • Turning Point Therapeutics Inc. - Overview
  • Turning Point Therapeutics Inc. - Product and service
  • Turning Point Therapeutics Inc. - Key offerings
  • Turning Point Therapeutics Inc. - Key customers
  • Turning Point Therapeutics Inc. - Segment focus
  • Currency conversion rates for US$
  • Research Methodology
  • Validation techniques employed for market sizing
  • Information sources
  • List of abbreviations
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Bio-Techne Corp.
  • F. Hoffmann-La Roche Ltd.
  • Helsinn Healthcare SA
  • Merck KGaA
  • Novartis AG
  • Pfizer Inc.
The publisher recognizes the following companies as the key players in the global anaplastic lymphoma kinase (ALK) inhibitors market: Betta Pharmaceuticals Co. Ltd., Bio-Techne Corp., Chia Tai Tianqing Pharmaceutical Group Co. Ltd., F. Hoffmann-La Roche Ltd., Helsinn Healthcare SA, Merck KGaA, Novartis AG, Pfizer Inc., Takeda Pharmaceutical Co. Ltd., and Turning Point Therapeutics Inc.

Commenting on the report, an analyst from the research team said: 'The latest trend gaining momentum in the market is the expansion of research areas and combination therapies.'

According to the report, one of the major drivers for this market is the high target affinity and specificity of ALK inhibitors.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Note: Product cover images may vary from those shown

A selection of companies mentioned in this report includes:

  • Betta Pharmaceuticals Co. Ltd.
  • Bio-Techne Corp.
  • Chia Tai Tianqing Pharmaceutical Group Co. Ltd.
  • F. Hoffmann-La Roche Ltd.
  • Helsinn Healthcare SA
  • Merck KGaA
  • Novartis AG
  • Pfizer Inc.
  • Takeda Pharmaceutical Co. Ltd.
  • Turning Point Therapeutics Inc.
Note: Product cover images may vary from those shown